Showing results (31-40 of 38) with videos related to
Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 38 results.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 24, 2001
Phase I clinical trial of oral COL-3, a matrix metalloproteinase inhibitor, in patients with refractory metastatic cancerM A Rudek, W D Figg, V Dyer, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 1, 1995
Phase I and pharmacokinetic study of the multidrug resistance modulator dexverapamil with EPOCH chemotherapyW H Wilson, C Jamis-Dow, G Bryant, et al.Antiviral Research|May 13, 1999
A phase I trial of the pharmacokinetics, toxicity, and activity of KNI-272, an inhibitor of HIV-1 protease, in patients with AIDS or symptomatic HIV infectionR W Humphrey, K M Wyvill, B Y Nguyen, et al.Clinical Pharmacology and Therapeutics|July 1, 1992
Adaptive control with feedback strategies for suramin dosingM R Cooper, R Lieberman, R V La Rocca, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 1, 1996
Phase I study of paclitaxel in combination with cyclophosphamide and granulocyte colony-stimulating factor in metastatic breast cancer patientsA W Tolcher, K H Cowan, M H Noone, et al.Applied Optics|July 13, 2005
Interpretation of hyperspectral remote-sensing imagery by spectrum matching and look-up tablesCurtis D Mobley, Lydia K Sundman, Curtiss O Davis, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 13, 2001
A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancerW D Figg, W Dahut, P Duray, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 16, 2000
Phase I and pharmacokinetic study of farnesyl protein transferase inhibitor R115777 in advanced cancerJ Zujewski, I D Horak, C J Bol, et al.Pageof 4